Fentanyl buccal - Teva

Drug Profile

Fentanyl buccal - Teva

Alternative Names: E-fen buccal tablets; Effentora; Fentanyl buccal - Cephalon; Fentanyl citrate - Teva; Fentora; OraVescent® fentanyl; OVF

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CIMA LABS
  • Developer BMP Sunstone Corporation; CIMA LABS; M. D. Anderson Cancer Center; Taiho Pharmaceutical; Teva Pharmaceutical Industries
  • Class General anaesthetics; Opioid analgesics; Piperidines; Small molecules
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cancer pain
  • Phase II Dyspnoea
  • Preregistration Submission Withdrawal Pain
  • Discontinued Neuropathic pain

Most Recent Events

  • 06 Jun 2017 Efficacy data from a phase II trial in Dyspnoea (in cancer patients) reported at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 07 Apr 2015 No recent reports of development identified - Preregistration for Pain in USA (Buccal)
  • 07 Apr 2015 No recent reports of development identified - Preregistration for Neuropathic pain in USA (Buccal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top